HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
- 1 April 2009
- journal article
- review article
- Published by SAGE Publications in Diabetes and Vascular Disease Research
- Vol. 6 (2), 133-138
- https://doi.org/10.1177/1479164109336038
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- Alterations in the Glucose-Stimulated Insulin Secretory Dose-Response Curve and in Insulin Clearance in Nondiabetic Insulin-Resistant IndividualsJournal of Clinical Endocrinology & Metabolism, 1997
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive DiseaseDiabetes, 1995
- Ca(2+)-insensitive sustained contraction of skinned smooth muscle after acidic ADP treatmentAmerican Journal of Physiology-Cell Physiology, 1995
- Variations in Insulin-Stimulated Glucose Uptake in Healthy Individuals with Normal Glucose Tolerance*Journal of Clinical Endocrinology & Metabolism, 1987
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin WithdrawalDiabetes, 1984
- Evidence that Glucose Load Is an Important Determinant of Plasma Insulin Response in Normal SubjectsDiabetes, 1971
- Regulation of the Secretions of the PancreasAnnual Review of Medicine, 1970